ClinicalTrials.gg
Active, not recruitingNCT04318041Updated Sep 30, 2026

Evaluation of the Structural Modification Effect of Diacerein (Artrodar®) in Knee Osteoarthritic Patients

A Phase 3 interventional study of Artrodar and Placebos in Knee Osteoarthritis, sponsored by TRB Chemedica. Active, not recruiting at 1 site in Thailand. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by TRB Chemedica · Phase 3, Interventional, and Treatment

Updated Sep 30, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Osteoarthritis, Knee with a site in Thailand — 7 open to participants now, 9 under way, 2 of them phase 3. Osteoarthritis, Knee · Thailand.

Planned enrollment
10th of 40
128 · median 97
Started
2020
with 3 others
Phase 3
7 of 44
none open now
Registered
25th of 44
by date
Lead sponsor
2 of 44
TRB Chemedica

Among the 44 studies in Osteoarthritis, Knee with a site in Thailand, this one is the 10th largest by planned enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2020, is one of 7 in phase 3, and was the 25th registered.

Osteoarthritis, Knee

3,296 studies on the registry are indexed under Osteoarthritis, Knee; 625 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

7 of the 44 studies in Osteoarthritis, Knee with a site in Thailand are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 385 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 114 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Osteoarthritis, Knee with a site in Thailand, or all of them as a file.
02

Study summary

This study evaluates the structure-modifying effect of Diacerein (Artrodar ®) in knee osteoarthritic (OA) patients by measuring total cartilage volume from magnetic resonance imaging (MRI) of the knee. Half of participants will receive Diacerein (Artrodar ®), while the other half will receive a placebo.

Read the detailed description

Diacerein (Artrodar ®) participants take 1x1 with evening meal for 1 month (D1-D28) then 1x2 with morning and evening meal for 23 months (D29-end of study). Placebo participants take 1x1 with evening meal for 1 month (D1-D28) then 1x2 with morning and evening meal for 23 months (D29-end of study).

03

Conditions studied

  • Knee Osteoarthritis
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged between 40 and 65 years who diagnosed with primary OA knee (medial tibiofemoral compartment) according to ACR criteria
  2. Grade II-III OA severity that classified by the Kellgren-Lawrence classification
  3. Varus malalignment ≤ 15°
  4. (BMI) ≤ 30 kg/m2
  5. Pain on walking at 15 metres ≥ 30 mm using 100 mm visual analogue pain score (VAPS)
  6. Evidence of adequate methods in women of childbearing age

Exclusion criteria

Exclusion Criteria:

  1. Accompanying osteoarthritis of the hip of sufficient severity to interfere with the functional assessment of the knee
  2. Intra-articular treatment with any product ( in the last 3 months, glycosaminoglycans, hyaluronic acid in the last 6 months, etc.), joint lavage or arthroscopic procedures within 6 months before the start of the study
  3. Oral corticosteroids, oral symptomatic slow acting drug for OA (SYSADOA) treatment (chondroitin sulfate, glucosamine sulfate, piascledin, diacerein) within last 3 months
  4. Current treatment with anti-depressants, tranquilisers, antacids or antibiotics
  5. Poor general health or other conditions which would make regular hospital attendance difficult
  6. Primary inflammatory painful conditions of the knee (e.g. rheumatoid arthritis, psoriatic arthropathy, pseudo-gout)
  7. Painful knee conditions other than osteoarthritis (e.g. Sudeck's atrophy, intra-articular neoplasm, villonodular synovitis)
  8. Evolving arthritis requiring surgery within the coming year;
  9. Persistent diarrhoea (> 3 stools /24 h) or laxative use (any laxative use is to be stopped before inclusion in the trial)
  10. Severe gastrointestinal disorders, indications or history of severe gastrointestinal disorders (e.g. gastric or duodenal ulcers, ulcerative colitis, Crohn's syndrome, diverticulitis, recurrent pancreatitis)
  11. Renal insufficiency (estimate ≤ 60 ml/min/1.73 m2)
  12. Hepatic disease (transaminases > 2.5 x values (ULN) or total > 2 x ULN) or history of alcoholism and liver disease
  13. Severe parenchymal organ disease
  14. History of heart attack or stroke, or have had serious diseases of the heart such as congestive heart failure, or taking clopidogrel.
  15. Patient with diabetes mellitus (DM) who has heamoglobin A1c level > 8%
  16. Patient with hypertension who has systolic blood pressure > 150 mmHg or diastolic Blood pressure > 95 mmHg
  17. Pregnancy or lactation
  18. Participation in a drug clinical trial within the 3 months before the start of the study;
  19. Ascertained to the active ingredient diacerein, to similar compounds, to the or to paracetamol, naproxen, and omeprazole
  20. for magnetic resonance imaging (MRI) assessment such as heart pacemaker, aneurysm clip or claustrophobia
  21. Knee size measured at lower thigh > 50 cm
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    diacerein (Artrodar)

    Drug: Artrodar

  • Placebo comparator
    placebo

    Drug: Placebos

Interventions

  • Diacerein (Artrodar): D1-D28 (1 month): Artrodar (50 mg) 1 x 1 with evening meal D29-end of study (23 months): Artrodar (50 mg) 1 x 2 with meal

  • DrugPlacebos

    Placebo: D1-D28 (1 month): Placebo 1 x 1 with evening meal D29-end of study (23 months) Placebo 1 x 2 with meal

06

What researchers measure

Primary outcomes

  1. Cartilage volume measured by MRI of the affected knee.

    Cartilage volume in cc

    Time frame: Change from Day 0 cartilage volume at Day 336, Day 672

  2. Bone marrow lesions measured by MRI of the affected knee.

    Bone marrow lesions in mm3

    Time frame: Change from Day 0 Bone marrow lesions at Day 336, Day 672

  3. Synovitis measured by MRI of the affected knee.

    Synovial tissue volume in mm3

    Time frame: Change from Day 0 Synovial tissue volume at Day 336, Day 672

  4. Joint space width at narrowest point at medial compartment measured by X-ray (Full extension, weight-bearing position)

    Joint space width in mm

    Time frame: Change from Day -7 to -30 Joint space width at Day 168, Day 336, Day 504, Day 672

Secondary outcomes

  1. Pain at rest

    Visual analogue scale (VAS) 0-100 mm. 0 is no pain, 100 is extreme pain.

    Time frame: Day 0, Day 28, Day 84, Day 168, Day 252, Day 336, Day 420, Day 504, Day 588, Day 672

  2. Pain on walking at 15 meters

    Visual analogue scale (VAS) 0-100 mm. 0 is no pain, 100 is extreme pain.

    Time frame: Day -7 to -30, Day 0, Day 28, Day 84, Day 168, Day 252, Day 336, Day 420, Day 504, Day 588, Day 672

  3. KOOs

    Knee and Osteoarthritis Outcome Score from 1-5 Likert scale score with higher scores denoting worse pain and disability.

    Time frame: Day 0, Day 28, Day 84, Day 168, Day 252, Day 336, Day 420, Day 504, Day 588, Day 672

  4. EQ5D5L

    EQ5D5L is a standardized instrument for measuring generic health status

    Time frame: Day 0, Day 28, Day 84, Day 168, Day 252, Day 336, Day 420, Day 504, Day 588, Day 672

  5. Time up-and-go test

    Time frame: Day 0, Day 28, Day 84, Day 168, Day 252, Day 336, Day 420, Day 504, Day 588, Day 672

  6. Physician and Patient's global assessment

    Visual analogue scale (VAS) 0-100 mm to assess efficacy and tolerability by physician and patient. 0 is not effective/ no tolerate, 100 is very effective/ very good.

    Time frame: Day 168, Day 336, Day 672

  7. Rescued medicine consumption

    Time frame: Day 28, Day 84, Day 168, Day 252, Day 336, Day 420, Day 504, Day 588, Day 672

  8. Oxford Knee Questionnaire

    1-5 Likert scale score with higher scores denoting worse pain and disability.

    Time frame: Day 0, Day 28, Day 84, Day 168, Day 252, Day 336, Day 420, Day 504, Day 588, Day 672

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Dec 2026, 73 months after the start.

Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's planned 73 months is above that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2020
First posted
Mar 23, 2020
StartActual
Nov 22, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Recruiting→Active, not recruiting
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04318041
Lead sponsor
TRB Chemedica
Responsible party
Sponsor
First posted
Mar 23, 2020
Start date
Nov 22, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 30, 2026

Study contacts

Nipaporn Jitsook
study director · TRB Chemedica

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diacerein

Start the discussion